Deep Dive: Page 3

Industry insights from our journalists


  • Image attribution tooltip
    Lydia Polimeni, National Institutes of Health
    Image attribution tooltip

    Will sky-high drug prices spur the US to use an obscure power over patents?

    New cell therapies as well as gene-based treatments like Zolgensma benefited from NIH funding of early-stage research. Advocates say the time is now for the government to invoke its "march-in" rights. 

    Jonathan Gardner • Dec. 4, 2019
  • Image attribution tooltip
    Brian Tucker, BioPharma Dive
    Image attribution tooltip

    Bankrupt biopharmas are rare. 2019 has some worried that's changing.

    Eleven biopharmas declared bankruptcy in 2019, more than any other year since at least 2011. Rising market pressures, coupled with legal liabilities, risk more companies falling to zero, experts warn.

    Andrew Dunn • Nov. 19, 2019
  • Image attribution tooltip
    Brian Tucker, BioPharma Dive
    Image attribution tooltip

    31 biopharmas at high risk of bankruptcy in 2020

    BioPharma Dive dug into data from a credit monitoring firm to identify drugmakers at high risk of going bankrupt, including companies like Teva, Bausch Health and Novavax.

    Andrew Dunn • Nov. 19, 2019
  • Image attribution tooltip
    Brian Tucker, BioPharma Dive
    Image attribution tooltip

    The running list of 2019 biopharma bankruptcies

    From antibiotic developers like Achaogen to opioid drugmakers like Purdue and Insys, 2019 saw an uptick in biopharmas filing for Chapter 11.

    Andrew Dunn • Nov. 19, 2019
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Give up board chairmanship? No thanks, US big pharma CEOs say

    Pfizer CEO Albert Bourla will soon head the pharma's board, too, adding another example of a large drugmaker with unified leadership.

    Jonathan Gardner • Oct. 16, 2019
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    First-of-its-kind trial in ALS spurs hope for brutal disease

    A so-called platform study will test five drugs at once, a design that experts say could become a model in rare disease drug development. 

    Andrew Dunn • Sept. 25, 2019
  • Image attribution tooltip
    Adeline Kon / BioPharma Dive
    Image attribution tooltip

    Cancer centers stretching to keep up with pharma's oncology interest

    Empty trials, bandwidth constraints and lingering issues with enrollment criteria are on display amid a boom in cancer drug research.

    Jacob Bell • Sept. 23, 2019
  • Image attribution tooltip
    Novo Nordisk
    Image attribution tooltip

    Is the future of diabetes treatment better drugs or better care?

    Drug manufacturers are trying to push the boundaries of glucose control, but cost concerns could rein in ambitions.

    Jonathan Gardner • Sept. 23, 2019
  • Public trust in drugmakers is at an all-time low. Can biopharma recover?

    Leaders are grappling with how to improve the industry's reputation at a time when the broader business world is under increased scrutiny.

    Andrew Dunn • Sept. 11, 2019
  • Image attribution tooltip
    Amgen
    Image attribution tooltip

    Amgen puts its KRAS hopes on 'Navy Seals' team of drug hunters

    Found in many solid tumors, mutant KRAS is cancer research's white whale. Amgen's drug looks the most promising to emerge from decades of failed efforts, but others are close behind. 

    Ned Pagliarulo • Aug. 30, 2019
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Amyloid's last hope? Prevention studies next big test for Alzheimer's research

    The DIAN-TU trial, studying patients genetically predisposed to Alzheimer's, could help decide the fate of what's been the dominant hypothesis of the disease's cause.

    Jonathan Gardner • Aug. 29, 2019
  • Image attribution tooltip
    Kendall Davis / BioPharma Dive
    Image attribution tooltip

    Unblinded: Rebekah Gee's drug pricing experiment in Louisiana

    Louisiana's health secretary negotiated a new payment model with Gilead for one of the poorest states in the country. Could it spread nationwide?

    Andrew Dunn • Aug. 28, 2019
  • Image attribution tooltip
    Brian Tucker, BioPharma Dive
    Image attribution tooltip

    Number of female biotech CEOs remains 'shockingly low,' putting spotlight on BIO

    "I need more from BIO," the group's diversity chair and Halozyme chief Helen Torley told BioPharma Dive. More than 90% of CEOs running the industry's top companies are men.

    Andrew Dunn • July 31, 2019
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Once 'bodies for hire,' CROs are finding a new role as data specialists

    Drugmakers and regulators are paying more attention to what real-world data can prove — driving demand for CROs to help keep up.

    Jacob Bell • June 28, 2019
  • Image attribution tooltip
    Kendall Davis / BioPharma Dive
    Image attribution tooltip

    Unblinded: Kevin Gorman on Neurocrine's rise, fall and future

    The biotech's share price fell from $70 to $2, and its headcount shrunk by nearly 90%. So how did Neurocrine make it through?

    Andrew Dunn • June 18, 2019
  • Image attribution tooltip
    Getty / Edited by BioPharma Dive
    Image attribution tooltip

    The gene therapy era has arrived. So have the challenges.

    With multiple gene therapies nearing market, the U.S. systems of reimbursement, regulation and research are being put to the test.

    Andrew Dunn • June 7, 2019
  • Woman with briefcase looking up at towers of cash.
    Image attribution tooltip
    Brian Tucker, BioPharma Dive
    Image attribution tooltip

    Follow the money: How biopharma CEOs and workers got paid in 2018

    Which CEOs made the most? The least? Does biotech pay better than pharma? BioPharma Dive pulled data from hundreds of proxy statements to find out.

    Andrew Dunn • May 28, 2019
  • Image attribution tooltip
    Yujin Kim / BioPharma Dive
    Image attribution tooltip

    No one knows the size of the NASH market

    Industry is still using a broad estimate for the NASH population, which has led to very different views on the size of the potential market opportunity.

    Jacob Bell • May 16, 2019
  • Image attribution tooltip
    Danielle Ternes / BioPharma Dive
    Image attribution tooltip

    On the path to patients, NASH drugs may hit a payer roadblock

    Wall Street estimates and clinical data suggest the earliest NASH drugs could come with limited efficacy but high price tags. Healthcare providers fear that won't sit well with payers.

    Jacob Bell • May 15, 2019
  • Image attribution tooltip
    Yujin Kim / BioPharma Dive
    Image attribution tooltip

    Will a big needle burst the NASH bubble?

    With less invasive tests still a few years off, doctors worry liver biopsies will limit access to the initial wave of NASH drugs — if any make it to market. 

    Jacob Bell • May 14, 2019
  • Image attribution tooltip
    Novartis
    Image attribution tooltip

    Pharma, late to digital game, rushes to catch up

    In the past two years, six of the largest pharmas appointed chief digital or information officers to top management for the first time, a signal of growing industry interest in revamping how it does business.

    Ned Pagliarulo • May 13, 2019
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Biopharma happily takes the tax cuts, but the jobs are harder to find

    The tax burden of U.S.-based drugmakers shrank by nearly one-quarter following the 2017 Republican tax bill, but jobs edged up only slightly, a BioPharma Dive analysis found.

    Jonathan Gardner • May 9, 2019
  • Image attribution tooltip
    Kendall Davis / BioPharma Dive, photo from Incyte
    Image attribution tooltip

    Unblinded: Hervé​ Hoppenot on solving Incyte's 'single asset syndrome'

    Last April, a closely watched study of an Incyte cancer drug failed, sending the biotech back to the drawing board. This year could help answer what's next. 

    Ned Pagliarulo • April 10, 2019
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Aducanumab's failure puts pressure on field to look beyond amyloid

    "At this point, we've done the right experiment and the hypothesis didn't hold true," said Howard Fillit, chief science officer of the Alzheimer’s Drug Discovery Foundation.

    Ned Pagliarulo • March 22, 2019
  • Image attribution tooltip
    Kendall Davis / BioPharma Dive; image from the Milken Institute
    Image attribution tooltip

    Unblinded: Scott Gottlieb on biosimilars' precarious moment and the gene therapy boom

    The outgoing FDA chief spoke with BioPharma Dive a day before his surprise resignation, detailing how drugmaker "shenanigans" have evolved and weighing in on gene therapy's inflection point.

    Andrew Dunn • March 12, 2019